• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Spinal Cord and Cranial Bing-Neel Syndrome Complicated by Stroke (P6.018)
CONCLUSIONS: Our case highlights a novel presentation of Bing-Neel Syndrome that responded well to systemic and intrathecal therapies. Bing-Neel Syndrome should be considered in patients with Waldenström’s macroglobulinemia who present with central nervous system ischemia and/or myelopathy as early recognition and treatment may prevent development of irreversible neurological damage. Study Supported by: n/aDisclosure: Dr. Vargas has nothing to disclose. Dr. Dixit has nothing to disclose. Dr. Quigley has nothing to disclose. Dr. Testai has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Vargas, A., Dixit, K., Quigley, J., Testai, F. Tags: Cerebrovascular Disease and Interventional Neurology II ePosters Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Recurrent ischemic stroke related to Waldenström's macroglobulinemia
Waldenström's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma which was first described in 1944. The disease is characterized by neoplastic proliferation of B lymphocytes and excessive production of monoclonal immunoglobulin M (IgM). The leading clinical features are lymphadenopathy and/or splenomegaly, anemia and hyperviscosity syndrome.
Source: Journal of Critical Care - November 15, 2013 Category: Intensive Care Authors: Jorge Hidalgo, Pedro Arriaga Tags: WFSICCM Abstracts Source Type: research

Spinal cord and cranial Bing-Neel Syndrome complicated by cerebral ischemia: A case report
Waldenström's macroglobulinemia (WM) is a B-cell malignancy characterized by lymphoplasmacytic lymphoma (LPL) within the bone marrow and an IgM monoclonal gammopathy in the blood. Symptoms may include weakness or fatigue, anorexia and weight loss, bleeding from the gums and nose, headache, blurred vision, peripheral neuropathy, and even stroke from hyperviscosity. The direct infiltration of the central nervous system (CNS), either as a diffuse leptomeningeal form or tumoral form is an exceedingly rare complication of WM, recognized as Bing-Neel Syndrome (BNS) [1].
Source: Journal of the Neurological Sciences - April 24, 2016 Category: Neurology Authors: Alejandro Vargas, Karan S. Dixit, John G. Quigley, Fernando D. Testai Tags: Letter to the Editor Source Type: research

A Rare Neurological Complication of Waldenstroms Macroglobulinemia (P5.183)
Conclusions:Diagnostic approach to bilateral FNP should evaluate for: traumatic (skull fractures), infectious (classically Lyme disease), metabolic (diabetes), autoimmune (sarcoidosis, Guillain-Barré syndrome), congenital (Moebius syndrome) and neoplastic (brainstem tumors) entities. WM is a rare cause, a condition due to low-grade B cell lymphoma where lymphoplasmacytoid cells infiltrate different tissues and secrete monoclonal IgM. Peripheral neuropathy develops in 15–30% of the cases, usually a chronic, progressive, symmetric, predominantly distal polyneuropathy. Facial nerve impairment is unusual, caused b...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Acosta, G. T., Gadhia, R., Leslie-Mazwi, T. Tags: Neuro-oncology: Brain and CNS Metastases Source Type: research

Vestibulocochlear nerve dysfunction as initial manifestation of Waldenstrom Macroglobulinemia (P5.193)
Conclusions:Clinical findings from this case demonstrated early vascular complications of multiple peripheral neurosensory systems secondary to WM-related hyperviscosity. Early recognition of symptoms through detailed history taking and neurological examination is necessary for a correct diagnosis and better outcome.Disclosure: Dr. Humayun has nothing to disclose. Dr. Panjwani has nothing to disclose. Dr. Li has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Humayun, M., Panjwani, S., Li, H. Tags: Neuro-ophthalmology/Neuro-otology I Source Type: research

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research

Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer
A 76-year-old female with obesity, hypertension, persistent atrial fibrillation, and heart failure with preserved ejection fraction is started on ibrutinib 420 mg once daily for Waldenstrom ’s macroglobulinemia. Due to concern for drug-drug interactions, her amiodarone is decreased from 200 to 100 mg daily, and she is continued on metoprolol succinate 100 mg daily and apixaban 5 mg twice daily. She presents to the clinic one month later with extensive superficial ecchymoses, and her apixaban dose is reduced to 2.5 mg twice daily due to concerns that this may reflect the combined antiplatelet effects of ibrutinib and anti...
Source: Heart Rhythm - April 27, 2021 Category: Cardiology Authors: Shiv Bagga, Sourbha S. Dani, Bruce G. Hook, Anju Nohria, Sarju Ganatra Source Type: research